A Phase I/II Study of a 72-h Continuous Infusion of Etoposide in Advanced Soft Tissue Sarcoma
Purpose. The study was performed to assess the antitumour activity and toxicity of a 72-h continuous infusion of single-agent etoposide as second-line treatment for patients with locally advanced or metastatic soft tissue sarcoma (STS), following reports of substantial activity using this schedule o...
Main Authors: | Charles R. Crawley, Ian R. Judson, Mark Verrill, Catherine Hill, Florence I. Raynaud |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
1997-01-01
|
Series: | Sarcoma |
Online Access: | http://dx.doi.org/10.1080/13577149778236 |
Similar Items
-
Adjuvant Chemotherapy of Soft Tissue Sarcoma—Current Status
by: Ian Judson
Published: (2000-01-01) -
EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma
by: H. Jan Keizer, et al.
Published: (1997-01-01) -
Guidelines for the Management of Soft Tissue Sarcomas
by: Robert Grimer, et al.
Published: (2010-01-01) -
Efficacy of combination-chemotherapy with pirarubicin, ifosfamide, and etoposide for soft tissue sarcoma: a single-institution retrospective analysis
by: Shiro Saito, et al.
Published: (2020-09-01) -
Symptom Burden, Survival and Palliative Care in Advanced Soft Tissue Sarcoma
by: Nicholas J. Gough, et al.
Published: (2011-01-01)